Update on CVP RX?

As CVP (and other EB's) are moving away from their generalist (M&A/RX) programs and now having their analysts focus mainly on one or the other, I'm curious to hear people's opinions on CVP's RX group now, in terms of how prestigious it is compared to other top EB groups. 

1) Do these analysts get the same exit opps as CVP analysts doing M&A?

2) Is being in CVP RX just as top tier as being in CVP's former generalist program?

3) How hard is it to break into CVP RX?

All insights are appreciated. thanks 

5 Comments
 
Most Helpful

CVP has used a “major/minor” system for the last several years where analysts choose to specialize in either M&A or RX. It’s primarily an internal designation though and externally people mostly just regarded as an analyst at Centerview. Also given size of group relative to M&A, RX majors get more of a generalist experience and are staffed on M&A deals too. Exit opps are broadly the same (actually know an RX major who went to VC and another who went to MF growth PE year before). 

CVP’s RX platform is quite small (4-5 partners and full team of 15-20 “majors”). As a result of sheer size, won’t be as competitive in league tables relative to your usual suspects (HL’s RX group is ~250 people and basically half the size of the entire CVP organization). Despite this, they have some pretty impressive creds. Specialize more in complex situations and really been crushing it in the last 2 years or so. Led high profile company-side deals like SVB, Credit Suisse and Celsius Network during latest financial crisis and have developed a rep in liability management with one of the first “pari plus” LM deals and big roles in others precedent setting situations. In my experience, I’d say in terms of LMEs, it’s PJT and Evercore in top 2 and CVP as a pretty good 3rd. They have been on every Clearlake deal (them or PJT for company side), which is and will continue to be a gold mine of RX fees given how well Clearlake’s fund is doing. 

All in all, probably tier 2 RX shop but with a unique angle, so not exactly apples-to-apples.

Re: breaking in, as far as I know it’s basically the same interview process as M&A (you interview with both RX and M&A majors) but will have extra interviews with RX partners. 

 

Both posters above are right. You apply separately but the superday is the same, albeit with potentially a few RX partner interviews

 

Aut ipsam ullam rerum ducimus fugit ab quia. Ullam veritatis est consequatur facilis provident adipisci incidunt. Repellendus officiis eum a excepturi quaerat aut.

Magni non at dolorem laudantium eveniet et sint. Enim molestiae repellat odio quam rerum ipsum exercitationem.

Consequatur atque alias at cupiditate velit quis sint. Molestias quo sint molestias accusantium aut. Nesciunt quia deleniti pariatur eveniet libero. A quod impedit est nulla fuga perferendis.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.8%
  • Evercore 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 05 98.3%
  • JPMorgan No 97.7%
  • Goldman Sachs 02 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (44) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (79) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”